The Cooper Companies, Inc., together with its subsidiaries, develops, manufactures, and markets contact lens wearers. The company operates in two segments, CooperVision and CooperSurgical. The CooperVision segment offers spherical, toric, and multifocal contact lenses that address vision challenges, such as astigmatism, presbyopia, and myopia. Its CooperSurgical segment focuses on family and women's health care, which provides fertility products and services, medical devices, and contraception, as well as cryostorage, such as cord blood and cord tissue storage. This segment offers Paragard, a hormone-free intrauterine device; and fertility consumables and equipment, donor gamete services, and genomic services, including genetic testing. The company sells its products to distributors, group purchasing organizations, eye care and health care professionals, including independent practices, corporate retailers, hospitals and clinics, and authorized resellers. The Cooper Companies, Inc. was founded in 1958 and is headquartered in San Ramon, California.

Currency in USD	2025
Operating Income	682.90 Million
Income Before Tax	566.50 Million
Income Tax Expense	191.60 Million
Net Income	374.90 Million
Eps	1.88
Epsdiluted	1.87
Weighted Average Shs Out	199.10 Million
Weighted Average Shs Out Dil	200.00 Million
Research And Development Expenses	172.20 Million
Selling General And Administrative Expenses	1.63 Billion
Depreciation And Amortization	377.40 Million
Interest Expense	100.00 Million
Interest Income	N/A
Net Interest Income	-100 Million
Premiums Earned	N/A
Policyholder Benefits	N/A
Gross Profit	2.68 Billion
Ebitda	1.06 Billion
Source	edgar
Ebit	666.50 Million

The Cooper Companies, Inc. Annual Reports (10-K)